105 related articles for article (PubMed ID: 34731787)
1. Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis.
Berger D; Bauer K; Kornauth C; Gamperl S; Stefanzl G; Smiljkovic D; Sillaber C; Bettelheim P; Knöbl P; Schiefer AI; Greiner G; Thalhammer R; Hoermann G; Schwarzinger I; Staber PB; Sperr WR; Valent P
Neoplasia; 2021 Dec; 23(12):1183-1191. PubMed ID: 34731787
[TBL] [Abstract][Full Text] [Related]
2. Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle.
Wang X; Yuan L; Lu B; Lin D; Xu X
Exp Ther Med; 2023 Dec; 26(6):574. PubMed ID: 38023359
[TBL] [Abstract][Full Text] [Related]
3. A case report of atypical chronic myeloid leukemia with complete hematological and major molecular response to Venetoclax/Azacitidine treatment.
Chen H; Wang N; Li Y; Xie X; Yang Y
Front Oncol; 2024; 14():1327834. PubMed ID: 38590658
[TBL] [Abstract][Full Text] [Related]
4. Hemophagocytic Lymphohistiocytosis Secondary to Refractory Acute Myeloid Leukemia Resolved after Second-Line Treatment with Azacitidine plus Venetoclax.
Zorzetto F; Scalas A; Longu F; Isoni MA; Angelucci E; Fozza C
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024011. PubMed ID: 38223479
[No Abstract] [Full Text] [Related]
5. Venetoclax and Azacitidine in the Treatment of
Ma J; Morimoto K; Pulsipher MA; Parekh C
JCO Precis Oncol; 2023 Jun; 7():e2200693. PubMed ID: 37315262
[No Abstract] [Full Text] [Related]
6. Acute basophilic leukemia in a patient with down syndrome: A case report and review of literature.
Singh A; Shetty D; Patil J; More M; Chatterjee G; Rajpal S; Patkar NV; Subramanian PG; Gujral S; Tembhare PR
Int J Lab Hematol; 2023 Dec; 45(6):972-978. PubMed ID: 37334558
[No Abstract] [Full Text] [Related]
7. Azacitidine for Acute Myeloid Leukemia: Why One Dose Does Not Fit All.
Cojutti PG; Pea F
Clin Pharmacol Ther; 2024 Mar; 115(3):403. PubMed ID: 38158606
[No Abstract] [Full Text] [Related]
8. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
[No Abstract] [Full Text] [Related]
9. A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.
Nekoukar Z; Moghimi M; Salehifar E
Blood Res; 2021 Dec; 56(4):229-242. PubMed ID: 34776414
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Yamamoto K; Shinagawa A; DiNardo CD; Pratz KW; Ishizawa K; Miyamoto T; Komatsu N; Nakashima Y; Yoshida C; Fukuhara N; Usuki K; Yamauchi T; Asada N; Asou N; Choi I; Miyazaki Y; Honda H; Okubo S; Kurokawa M; Zhou Y; Zha J; Potluri J; Matsumura I
Jpn J Clin Oncol; 2022 Jan; 52(1):29-38. PubMed ID: 34739075
[TBL] [Abstract][Full Text] [Related]
11. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill
Post SM; Ma H; Malaney P; Zhang X; Aitken MJL; Mak PY; Ruvolo VR; Yasuhiro T; Kozaki R; Chan LE; Ostermann LB; Konopleva M; Carter BZ; DiNardo C; Andreeff MD; Khoury JD; Ruvolo PP
Haematologica; 2022 Jun; 107(6):1311-1322. PubMed ID: 34732043
[TBL] [Abstract][Full Text] [Related]
12. Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors.
Jang HJ; Woo YM; Naka K; Park JH; Han HJ; Kim HJ; Kim SH; Ahn JS; Kim T; Kimura S; Zarabi S; Lipton JH; Minden MD; Jung CW; Kim HJ; Kim JW; Kim DDH
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771705
[TBL] [Abstract][Full Text] [Related]
13. Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine.
Pescia C; Boggio F; Croci GA; Cassin R; Barella M; Pettine L; Reda G; Sabattini E; Finelli C; Gianelli U
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768330
[TBL] [Abstract][Full Text] [Related]
14. A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.
Webster JA; Robinson TM; Blackford AL; Warlick E; Ferguson A; Borrello I; Zahurak M; Jones RJ; Smith BD
Leuk Res; 2021 Dec; 111():106737. PubMed ID: 34768161
[TBL] [Abstract][Full Text] [Related]
15. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
Garcia-Manero G; Döhner H; Wei AH; La Torre I; Skikne B; Beach CL; Santini V
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):236-250. PubMed ID: 34758945
[TBL] [Abstract][Full Text] [Related]
16. A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs.
Amir M; Javed S
Front Genet; 2021; 12():742802. PubMed ID: 34745216
[TBL] [Abstract][Full Text] [Related]
17. RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
Chow S; Tang K; Al-Abri M; Hall V; Tremblay-Lemay R; Rashedi I; Tsui H; Chan SM
Leuk Res; 2021 Dec; 111():106735. PubMed ID: 34735933
[No Abstract] [Full Text] [Related]
18. Keeping up with venetoclax for leukemic malignancies: key findings, optimal regimens, and clinical considerations.
Siddiqui M; Konopleva M
Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1497-1512. PubMed ID: 34791957
[TBL] [Abstract][Full Text] [Related]
19. Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1.
Lu YH; Huang ZY
Mol Med; 2021 Nov; 27(1):148. PubMed ID: 34781898
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
